(Q35782823)

10 August 2017

1 reference

title

Zoledronic acid: a review of its use in patients with advanced cancer (English)

1 reference

10 August 2017

1 reference

1

Caroline M Perry

1 reference

10 August 2017

2

David P Figgitt

1 reference

10 August 2017

1 January 2004

1 reference

10 August 2017

1 reference

10 August 2017

64

1 reference

10 August 2017

1197-1211

1 reference

10 August 2017

11

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200464110-00004

10 August 2017

0 references

cites work

Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma

1 reference

12 December 2020

Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.

1 reference

12 December 2020

Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound

1 reference

12 December 2020

Bone microenvironment-related growth factors modulate differentially the anticancer actions of zoledronic acid and doxorubicin on PC-3 prostate cancer cells.

1 reference

12 December 2020

Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group

1 reference

12 December 2020

Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion

1 reference

12 December 2020

Zoledronic acid: a new parenteral bisphosphonate

1 reference

12 December 2020

The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel

1 reference

12 December 2020

Should all breast cancer patients with symptomatic bone metastasis be treated with bisphosphonates? The case against

1 reference

12 December 2020

A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease

1 reference

12 December 2020

Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer

1 reference

12 December 2020

Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma

1 reference

12 December 2020

Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models

1 reference

12 December 2020

The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells

1 reference

12 December 2020

Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment

1 reference

12 December 2020

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

1 reference

12 December 2020

Effects of short-term treatment with the bisphosphonates zoledronate and pamidronate on rat bone: a comparative histomorphometric study on the cancellous bone formed before, during, and after treatment

1 reference

12 December 2020

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer

1 reference

12 December 2020

Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.

1 reference

12 December 2020

Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials

1 reference

12 December 2020

A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases

1 reference

12 December 2020

Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases

1 reference

12 December 2020

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial

1 reference

12 December 2020

A dose-finding study of zoledronate in hypercalcemic cancer patients

1 reference

12 December 2020

Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone

1 reference

12 December 2020

Effects of two novel bisphosphonates on bone cells in vitro.

1 reference

12 December 2020

The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function

1 reference

12 December 2020

Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial

1 reference

12 December 2020

Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases

1 reference

12 December 2020

Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts

1 reference

12 December 2020

Zoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancy

1 reference

12 December 2020

Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells

1 reference

12 December 2020

In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates

1 reference

12 December 2020

Variation in survival of European children with acute lymphoblastic leukaemia, diagnosed in 1978--1992: the EUROCARE study.

1 reference

12 December 2020

Renal Failure with the Use of Zoledronic Acid

1 reference

12 December 2020

Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells

1 reference

12 December 2020

Bisphosphonates induce breast cancer cell death in vitro

1 reference

12 December 2020

Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts

1 reference

12 December 2020

10.2165/00003495-200464110-00004

Identifiers

DOI

1 reference

PubMed ID

15161327

Dimensions Publication ID

10 August 2017

0 references

1 reference

PubMed ID

15161327